Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours

doi:doi:10.1038/sj.bjc.6600554

British Journal of Cancer (2002) 87, 1162–1165. doi:10.1038/sj.bjc.6600554 www.bjcancer.com
Published online 4 November 2002

Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours

H Özda g breve ¹, S J Batley¹, A Försti^1,4, N G Iyer¹, Y Daigo¹, J Boutell², M J Arends³, B A J Ponder¹, T Kouzarides² and C Caldas¹

¹Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge CB2 2XZ, UK
²Wellcome/CRC Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, UK
³Molecular Histopathology, University of Cambridge Pathology Department, Addenbrooke's Hospital, Box 235, Level 3, Hills Road, Cambridge CB2 2QQ, UK

Correspondence: C Caldas, E-mail: cc234@cam.ac.uk

⁴Current address: Department of Biosciences at Novum, Karolinska Institute, 14157 Huddinge, Sweden

Received 19 April 2002; Revised 4 July 2002; Accepted 31 July 2002.

Top

Abstract

In this study we screened the histone acetyltransferases CBP and PCAF for mutations in human epithelial cancer cell lines and primary tumours. We identified two CBP truncations (both in cell lines), seven PCAF missense variants and four CBP intronic microdeletions. These data suggest that neither gene is commonly inactivated in human epithelial cancers.